Ainos, Inc. reports developments tied to its transition toward AI-powered scent intelligence and industrial sensing. The company centers its commercial focus on AI Nose, an electronic olfaction platform that uses sensor arrays and proprietary artificial intelligence models, including its Smell Language Model, to convert volatile organic compound and scent signals into machine-readable Smell ID data.
Recurring news themes include AI Nose commercialization across semiconductor manufacturing, robotics, smart infrastructure, and healthcare-related environments; distribution and deployment relationships; industry classification updates; and financial results connected to the platform. Ainos also maintains a therapeutic-development program around VELDONA, a low-dose oral interferon program targeting rare, autoimmune, and infectious diseases.
Ainos (AIMD) completed the required VELDONA data delivery and technology transfer under its license agreement, triggering a $600,000 initial license payment. The partner confirmed completion in writing on September 29; payment is due within 15 business days under the agreement.
The delivery covers clinical and regulatory materials for Sjögren's disease and thrombocytopenia. The payment forms part of a previously announced potential $10 million licensing framework, with conditional payments tied to the first sublicense and licenses for 15 additional indications. Ainos is separately entitled to 25% of net sublicensing revenue, as defined in the agreement. Ainos also delivered 1,400 AI Nose systems to ASE.
Ainos (AIMD) has completed delivery of 1,400 AI Nose systems to ASE Technology Holding under their semiconductor agreement. The approximately $2.1 million, three-year agreement covers hardware and subscription-based services for ASE’s semiconductor packaging and testing operations. Ainos previously received approximately $350,000 in customer prepayments. Having fulfilled its delivery obligations, the company expects the systems to contribute to third-quarter 2026 revenue; final amounts remain subject to quarter-end closing.
ASE has deployed first-phase systems across different locations, primarily in advanced packaging. Ainos has begun discussions about a larger second phase based on an existing memorandum of understanding, but a separate agreement remains under negotiation. Predictive and yield-related benefits still require validation against operating and quality events.
Ainos (AIMD) detailed its September 24 VELDONA license agreement, including a $600,000 initial fee and partner-funded development.
The licensee will fund and execute assigned clinical and regulatory work for globally licensed Sjögren's disease and thrombocytopenia indications. Ainos expects to complete contractual delivery shortly. The fee is payable within 15 business days after payment conditions are satisfied; it does not require trial completion or marketing approval. Ainos retains ownership of its existing platform, subject to licensed rights, and is entitled to 25% of applicable net sublicensing revenue.
A potential $10 million framework includes the initial fee, conditional licenses for 15 additional indications and a separate first-sublicense fee. It is neither guaranteed revenue nor a cap on total payments. Additional licenses require separate agreements; qualifying sublicenses and separately negotiated product supply could provide other payments. Historical clinical records can inform development, but further evidence is needed under current standards.
Ainos (AIMD) signed a VELDONA license agreement with BioPhoenix on September 24, 2026, establishing a conditional $10 million collaboration framework. BioPhoenix receives an exclusive worldwide license for Sjögren's disease and thrombocytopenia. The framework includes an initial fee, consideration if 15 additional indication licenses are completed under separate agreements, and a one-time fee after BioPhoenix's first third-party sublicense. The $10 million is not guaranteed revenue.
BioPhoenix will fund and carry out clinical and regulatory work assigned to it for the two initial indications. Ainos retains ownership of its existing VELDONA platform and is entitled to 25% of applicable net sublicensing revenue. BioPhoenix-funded development spending, potential product supply revenue and downstream revenue sharing are outside the $10 million framework. Neither party is required to complete all 15 additional licenses.
Ainos (AIMD) is highlighted in a new VASRO GmbH research update for progressing its AI Nose platform in semiconductor applications. The report cites Ainos' transition from validation to initial commercial front-end semiconductor orders and an approximately $2.1 million back-end semiconductor subscription program as markers of growing commercial scale.
VASRO also emphasizes Ainos' proprietary real-world chemical dataset, which has surpassed 1 billion records, as a key strategic asset underpinning its Chemical Intelligence strategy. As AI Nose deployments expand, the company said the resulting semiconductor-specific chemical data can deepen its library, support additional use cases, and potentially reinforce further deployment and adoption.
Ainos (AIMD) announced that its second-generation AI Nose platform is moving from validation into initial commercial deployment in front-end semiconductor manufacturing, with the company receiving initial commercial orders from a front-end semiconductor customer as of September 14, 2026.
The transition follows a validation program begun in March 2026 that involved plans to deploy about 200 AI Nose systems in front-end wafer fabrication environments. Ainos launched the second-generation platform in August 2026 with upgrades to software, firmware, edge AI, hardware reliability, modular design, over-the-air capabilities, and fleet management for continuous industrial use. Alongside this, Ainos’ proprietary real-world chemical dataset has surpassed 1 billion records, up from about 878 million in August 2026, strengthening its Chemical Intelligence data foundation. AI Nose acts as a physical edge node to digitize chemical signatures, adding a chemical perception layer to existing industrial monitoring systems.
Ainos (AIMD) has secured three new Japanese patents for its AI Nose electronic nose technologies and their integration with robotic systems.
The patents cover gas exchange systems, rapid chemical detection, and robots equipped with electronic noses, extending Ainos' strategy to build a Chemical Perception Layer for Physical AI. With these grants, the company now holds 124 patent assets worldwide, spanning chips, sensing architectures, chemical molecules, devices, systems and AI-enabled applications. Ainos positions AI Nose as a physical edge node that generates real-world chemical data for AI models, aiming to advance Chemical Intelligence for robots, autonomous machines and other Physical AI platforms.
Ainos (NASDAQ:AIMD) announced the global launch of Atmosphere Engine™, a modular platform that generates high-purity nitrogen and oxygen from ambient air on-site, extending the company’s AI-powered environmental sensing and Chemical Intelligence into active environmental management for AI infrastructure and semiconductor manufacturing.
The system is designed to create nitrogen-rich inert environments to help reduce oxidation and environmental degradation around high-value computing and fab equipment, while its building-block architecture allows capacity to scale from individual tools or zones to larger facilities. According to Ainos, engineering calculations indicate Atmosphere Engine is designed to use roughly one-third of the electricity of conventional molecular sieve-based systems under comparable conditions.
Ainos (NASDAQ:AIMD) announced the second generation of its AI Nose platform, combining upgraded software, firmware, Edge AI and industrial-grade hardware engineered for continuous 24/7 deployment in commercial and industrial environments. Each device acts as an intelligent edge node, locally processing chemical data and feeding Ainos' cloud-connected Smell AI network.
Ainos reported its Smell AI network has accumulated more than 878 million real-world smell data records, forming a growing foundation for what the company defines as Chemical Intelligence—digitizing complex chemical signatures so machines can analyze and learn from environmental changes across sectors such as semiconductor manufacturing, data centers, smart buildings, industrial safety, healthcare environments and robotics.
Ainos (NASDAQ:AIMD) reported that its AI Nose platform has surpassed 878 million real-world smell and chemical data points as of August 13, 2026, up from about 613 million on July 21. The dataset expanded by roughly 265 million points in 23 days, an increase of about 43%, primarily from semiconductor manufacturing and operating environments.
The company is advancing a planned deployment of 1,400 AI Nose systems, with additional systems being installed as Physical Edge Nodes. These nodes feed proprietary data into the ScentAI continuous learning architecture, supporting Ainos’ strategy to build Chemical Intelligence as a foundational layer for Physical AI.